Bone densitometry developer CompuMed edged closer to the black this year, reporting slightly higher revenues and a lower net loss for fiscal year 2002 (end-Sept. 30) compared to last year.
Total revenues for the year were $1,955,000, compared to $1,927,000 in fiscal 2001, according to the Los Angeles firm. The company's net loss was $494,000 for fiscal 2002, down sharply from the net loss of $897,000 reported last year.
Revenues from the firm's OsteoGram osteoporosis diagnostics increased to $121,000 in 2002 from $69,000 in 2001, owing to the preliminary launch of the product in international markets, CompuMed said. In 2002 the firm expanded its marketing strategy for OsteoGram to include select international markets as well as the primary care market in the U.S.
By AuntMinnie.com staff writersDecember 31, 2002
Related Reading
CompuMed files patent application, October 15, 2002
CompuMed’s OsteoGram approved for marketing in China, June 25, 2002
CompuMed revenues edge higher in Q2, May 15, 2002
CompuMed hires new management team, May 13, 2002
CompuMed revenues dip, February 14, 2002
Copyright © 2002 AuntMinnie.com
